EX-10.17 4 d517182dex1017.htm EX-10.17 [***] indicates material that has been omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission. A complete copy of this agreement, including redacted portions so...Capital Project Agreement • May 5th, 2020 • Pennsylvania
Contract Type FiledMay 5th, 2020 JurisdictionThis Agreement (the “Agreement”), is effective May 10, 2012 (the “Effective Date”) and is made by and between Iroko Pharmaceuticals, LLC, a Delaware limited liability company, whose principal place of business is at The Navy Yard Corporate Center, One Crescent Drive, Suite 400, Philadelphia, Pennsylvania 19112 (“Iroko”) and Catalent CTS, Inc., formerly known as Aptuit, Inc., a Delaware corporation, with offices located at 10245 Hickman Mills Drive, Kansas City, MO 64137 (“Catalent”).
CAPITAL PROJECT AGREEMENTCapital Project Agreement • June 27th, 2013 • Iroko Pharmaceuticals Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledJune 27th, 2013 Company Industry JurisdictionThis Agreement (the “Agreement”), is effective May 10, 2012 (the “Effective Date”) and is made by and between Iroko Pharmaceuticals, LLC, a Delaware limited liability company, whose principal place of business is at The Navy Yard Corporate Center, One Crescent Drive, Suite 400, Philadelphia, Pennsylvania 19112 (“Iroko”) and Catalent CTS, Inc., formerly known as Aptuit, Inc., a Delaware corporation, with offices located at 10245 Hickman Mills Drive, Kansas City, MO 64137 (“Catalent”).